Reviewing Rallybio (NASDAQ:RLYB) & Oxford BioMedica (OTCMKTS:OXBDF)

Rallybio (NASDAQ:RLYB) and Oxford BioMedica (OTCMKTS:OXBDF) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

Analyst Recommendations

This is a breakdown of current recommendations for Rallybio and Oxford BioMedica, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rallybio	1	0	0	0	1.00
Oxford BioMedica	0	0	0	0	0.00

Valuation & Earnings

This table compares Rallybio and Oxford BioMedica”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rallybio	$860,000.00	86.12	-$8.98 million	($2.56)	-5.47
Oxford BioMedica	$164.59 million	5.56	-$46.74 million	N/A	N/A

Rallybio has higher earnings, but lower revenue than Oxford BioMedica.

Profitability

This table compares Rallybio and Oxford BioMedica’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rallybio	-1,046.39%	-56.93%	-52.67%
Oxford BioMedica	N/A	N/A	N/A

Risk & Volatility

Rallybio has a beta of -1.1, suggesting that its share price is 210% less volatile than the S&P 500. Comparatively, Oxford BioMedica has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500.

Insider and Institutional Ownership

90.3% of Rallybio shares are owned by institutional investors. 10.3% of Rallybio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

About Rallybio

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.

About Oxford BioMedica

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, and adenoviral vectors. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.